Clinical trials: GBS, open to volunteers
Guillain-Barré Syndrome (GBS)
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barré syndrome (GBS) recover and whether it is safe.
- Trial name
- embridge (NCT07821762)
- Testing
- Empasiprubart IV, Intravenous immunoglobulin (IVIg)
- Volunteers
- 63 people
- Sponsor
- argenx
Guillain-Barre Syndrome
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
- Trial name
- NCT07020819
- Testing
- Tanruprubart
- Where
- 30 sites in United States, Denmark and 3 more
- Volunteers
- 30 people
- Sponsor
- Annexon, Inc.
Invasive Group B Streptococcus Disease, Group B Streptococcus
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
The goal of this registry is to collect and store important medical and non-health information on children from 0 to 18 years of age affected by early- (up to 24 hours after birth) and late-onset (up to 90 days after birth)…
- Conditions
- Invasive Group B Streptococcus Disease, Group B Streptococcus, Group B Streptococcal Infection, Group B Streptococcus (GBS) Disease
- Trial name
- COMPPASS (NCT06896526)
- Volunteers
- 10,000 people
- Sponsor
- Precia Group